600380 健康元
已收盘 03-19 15:00:00
资讯
新帖
简况
每周股票复盘：健康元（600380）为丽珠单抗担保4亿元
证券之星 · 03-08
每周股票复盘：健康元（600380）为丽珠单抗担保4亿元
健康元（600380）披露控股子公司丽珠集团收购越南IMP公司股权获越方批复，3月6日股价上涨2.85%
证券之星 · 03-06
健康元（600380）披露控股子公司丽珠集团收购越南IMP公司股权获越方批复，3月6日股价上涨2.85%
健康元（600380）披露为控股子公司提供担保进展，3月3日股价下跌1.51%
证券之星 · 03-03
健康元（600380）披露为控股子公司提供担保进展，3月3日股价下跌1.51%
健康元（600380）披露为控股子公司提供担保进展情况，2月4日股价上涨1.49%
证券之星 · 02-04
健康元（600380）披露为控股子公司提供担保进展情况，2月4日股价上涨1.49%
健康元药业集团拟使用不超过29亿元闲置自有资金进行委托理财
中金财经 · 01-31
健康元药业集团拟使用不超过29亿元闲置自有资金进行委托理财
健康元（600380）披露使用不超过29亿元闲置自有资金进行委托理财的公告，1月30日股价下跌0.93%
证券之星 · 01-30
健康元（600380）披露使用不超过29亿元闲置自有资金进行委托理财的公告，1月30日股价下跌0.93%
每周股票复盘：健康元（600380）任命张庆雷为公司副总裁
证券之星 · 01-18
每周股票复盘：健康元（600380）任命张庆雷为公司副总裁
健康元药业集团聘任张庆雷为副总裁，强化创新药研发与商业化布局
中金财经 · 01-17
健康元药业集团聘任张庆雷为副总裁，强化创新药研发与商业化布局
健康元(600380.SH)：莱康奇塔单抗注射液被纳入优先审评审批程序
智通财经 · 01-07
健康元(600380.SH)：莱康奇塔单抗注射液被纳入优先审评审批程序
丽珠医药(01513)：健康元拟将毛孩子49%股权转让给心有毛孩
智通财经 · 2025-12-30
丽珠医药(01513)：健康元拟将毛孩子49%股权转让给心有毛孩
每周股票复盘：健康元（600380）NS-041片获抑郁症临床试验批准
证券之星 · 2025-12-28
每周股票复盘：健康元（600380）NS-041片获抑郁症临床试验批准
健康元最新公告：莱康奇塔单抗注射液上市许可申请获受理
证券之星 · 2025-12-24
健康元最新公告：莱康奇塔单抗注射液上市许可申请获受理
健康元（600380）披露获得NS-041片抑郁症临床试验批准，12月22日股价上涨0.76%
证券之星 · 2025-12-22
健康元（600380）披露获得NS-041片抑郁症临床试验批准，12月22日股价上涨0.76%
健康元(600380.SH)下属子公司获得药物临床试验批准通知书
智通财经 · 2025-12-21
健康元(600380.SH)下属子公司获得药物临床试验批准通知书
健康元最新公告：控股子公司获得NS-041片新增抑郁症临床试验批准通知书国内尚无新一代靶向KCNQ2/3的药物上市
证券之星 · 2025-12-21
健康元最新公告：控股子公司获得NS-041片新增抑郁症临床试验批准通知书国内尚无新一代靶向KCNQ2/3的药物上市
健康元(600380.SH)：玛帕西沙韦胶囊获药品注册证书
智通财经 · 2025-12-11
健康元(600380.SH)：玛帕西沙韦胶囊获药品注册证书
健康元药业集团多款核心产品纳入新版国家医保目录
中金财经 · 2025-12-09
健康元药业集团多款核心产品纳入新版国家医保目录
健康元(600380.SH)及下属子公司共有218个产品纳入医保目录
智通财经 · 2025-12-08
健康元(600380.SH)及下属子公司共有218个产品纳入医保目录
健康元（600380）披露第二期中长期事业合伙人持股计划存续期六个月后届满提示，12月5日股价下跌0.24%
证券之星 · 2025-12-05
健康元（600380）披露第二期中长期事业合伙人持股计划存续期六个月后届满提示，12月5日股价下跌0.24%
健康元药业集团召开2025年第三季度业绩说明会，披露创新药进展与海外布局
中金财经 · 2025-11-26
健康元药业集团召开2025年第三季度业绩说明会，披露创新药进展与海外布局
加载更多
公司概况
公司名称：
健康元药业集团股份有限公司
所属行业：
医药制造业
上市日期：
2001-06-08
主营业务：
健康元药业集团股份有限公司的主营业务是医药产品及保健品研发、生产及销售。公司的主要产品是化学制剂、生物制品、化学原料药及中间体、中药制剂、诊断试剂及设备、保健食品。公司凭借扎实的研发生产实力成功入选2025中国药品研发综合实力50强。
发行价格：
24.80
{"stockData":{"symbol":"600380","market":"SH","secType":"STK","nameCN":"健康元","latestPrice":11.07,"timestamp":1773903600000,"preClose":11.24,"halted":0,"volume":9671143,"delay":0,"changeRate":-0.0151,"floatShares":1829000000,"shares":1829000000,"eps":0.7468,"marketStatus":"已收盘","change":-0.17,"latestTime":"03-19 15:00:00","open":11.19,"high":11.27,"low":11.04,"amount":108000000,"amplitude":0.0205,"askPrice":11.08,"askSize":340,"bidPrice":11.07,"bidSize":145,"shortable":0,"etf":0,"ttmEps":0.7468,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1773970200000},"marketStatusCode":5,"adr":0,"adjPreClose":11.24,"symbolType":"stock","openAndCloseTimeList":[[1773883800000,1773891000000],[1773896400000,1773903600000]],"highLimit":12.36,"lowLimit":10.12,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1829453386,"isCdr":false,"pbRate":1.36,"roa":"--","peRate":14.823246,"roe":"7.46%","epsLYR":0.74,"committee":0.21449,"marketValue":20252000000,"turnoverRate":0.0053,"status":1,"floatMarketCap":20252000000},"requestUrl":"/m/hq/s/600380","defaultTab":"news","newsList":[{"id":"2617668732","title":"每周股票复盘：健康元（600380）为丽珠单抗担保4亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2617668732","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617668732?lang=zh_cn&edition=full","pubTime":"2026-03-08 02:17","pubTimestamp":1772907430,"startTime":"0","endTime":"0","summary":"截至2026年3月6日收盘，健康元报收于11.19元，较上周的11.46元下跌2.36%。本周，健康元3月2日盘中最高价报11.46元。截至公告日，公司对外担保余额为212,437.62万元，占最近一期经审计净资产的14.62%，无逾期担保。本公司为丽珠集团提供反担保，比例为26.84%。因交易触发公开要约收购义务，LIAN SGP拟向IMP全体股东发出收购要约。2025年12月30日，公司再次召开董事会，同意推进要约收购并提交相关申请。近日，LIAN SGP已获得越南国家证券委员会对本次要约收购的批复。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030800000658.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0239","BK0046","BK0114","600380","BK0028","BK0188"],"gpt_icon":0},{"id":"2617365106","title":"健康元（600380）披露控股子公司丽珠集团收购越南IMP公司股权获越方批复，3月6日股价上涨2.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617365106","media":"证券之星","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617365106?lang=zh_cn&edition=full","pubTime":"2026-03-06 22:33","pubTimestamp":1772807597,"startTime":"0","endTime":"0","summary":"截至2026年3月6日收盘，健康元报收于11.19元，较前一交易日上涨2.85%，最新总市值为204.72亿元。健康元药业集团股份有限公司近日发布关于控股子公司丽珠集团拟公开收购越南IMP公司股权的进展公告。公告显示，健康元于2025年5月22日召开董事会，审议通过控股子公司丽珠集团拟通过境外全资附属公司LIAN SGP收购越南上市公司Imexpharm Corporation64.81%股份的议案。因交易触发公开要约收购义务，LIAN SGP拟向IMP全体股东发出收购要约。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030600040410.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000513","BK0114","BK0187","BK0028","BK0239","FVNmain","600380","BK0188","BK0077","BK0046"],"gpt_icon":0},{"id":"2616602329","title":"健康元（600380）披露为控股子公司提供担保进展，3月3日股价下跌1.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616602329","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616602329?lang=zh_cn&edition=full","pubTime":"2026-03-03 22:41","pubTimestamp":1772548878,"startTime":"0","endTime":"0","summary":"截至2026年3月3日收盘，健康元报收于11.1元，较前一交易日下跌1.51%，最新总市值为203.07亿元。近日，健康元药业集团股份有限公司发布《关于为控股子公司提供担保进展情况的公告》。截至公告日，公司对外担保余额为212,437.62万元，占最近一期经审计净资产的14.62%，无逾期担保。本公司为丽珠集团提供反担保，比例为26.84%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030300044621.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0077","BK0188","BK0028","600380","BK0114","BK0046"],"gpt_icon":0},{"id":"2608005398","title":"健康元（600380）披露为控股子公司提供担保进展情况，2月4日股价上涨1.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608005398","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608005398?lang=zh_cn&edition=full","pubTime":"2026-02-04 22:50","pubTimestamp":1770216628,"startTime":"0","endTime":"0","summary":"截至2026年2月4日收盘，健康元报收于11.59元，较前一交易日上涨1.49%，最新总市值为212.03亿元。该股当日开盘11.41元，最高11.6元，最低11.34元，成交额达1.45亿元，换手率为0.69%。近日，健康元药业集团股份有限公司发布《关于为控股子公司提供担保进展情况的公告》。截至公告日，公司对外担保余额为228,478.14万元，占最近一期经审计净资产的15.72%，无逾期担保。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020400041932.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","BK0077","600380","BK0188","BK0028","BK0114"],"gpt_icon":0},{"id":"2607078904","title":"健康元药业集团拟使用不超过29亿元闲置自有资金进行委托理财","url":"https://stock-news.laohu8.com/highlight/detail?id=2607078904","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607078904?lang=zh_cn&edition=full","pubTime":"2026-01-31 08:58","pubTimestamp":1769821102,"startTime":"0","endTime":"0","summary":"中访网数据 健康元药业集团股份有限公司于2026年1月30日召开第九届董事会第十六次会议，审议通过了关于使用闲置自有资金进行委托理财的议案。根据决议，为提高资金使用效率，公司及控股子公司拟使用总额不超过人民币29亿元的闲置自有资金开展委托理财业务，该额度在决议生效起12个月内可循环滚动使用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260131/31989079.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0114","BK0077","BK0239","BK0188","600380","BK0046","BK0028"],"gpt_icon":0},{"id":"2607604432","title":"健康元（600380）披露使用不超过29亿元闲置自有资金进行委托理财的公告，1月30日股价下跌0.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607604432","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607604432?lang=zh_cn&edition=full","pubTime":"2026-01-30 22:45","pubTimestamp":1769784313,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，健康元报收于11.67元，较前一交易日下跌0.93%，最新总市值为213.5亿元。该股当日开盘11.78元，最高11.92元，最低11.63元，成交额达1.85亿元，换手率为0.86%。近日，健康元药业集团股份有限公司发布《关于使用闲置自有资金进行委托理财的公告》。投资额度自董事会审议通过之日起12个月内有效，资金可滚动使用。该事项无需提交股东会审议，不构成关联交易。公司已制定风险控制措施，确保资金安全。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000047644.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0046","600380","BK0114","BK0077","BK0028","BK0239"],"gpt_icon":0},{"id":"2604919923","title":"每周股票复盘：健康元（600380）任命张庆雷为公司副总裁","url":"https://stock-news.laohu8.com/highlight/detail?id=2604919923","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604919923?lang=zh_cn&edition=full","pubTime":"2026-01-18 02:49","pubTimestamp":1768675747,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，健康元报收于11.79元，较上周的11.97元下跌1.5%。本周，健康元1月13日盘中最高价报12.41元。本周关注点公司公告汇总：健康元任命张庆雷为公司副总裁，负责药政法规事务及创新药临床与上市工作。公司公告汇总健康元药业集团股份有限公司于2026年1月16日召开九届董事会十五次会议，审议通过任命张庆雷先生为公司副总裁的议案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800000640.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0239","BK0046","BK0114","600380","BK0028","BK0188"],"gpt_icon":0},{"id":"2604729910","title":"健康元药业集团聘任张庆雷为副总裁，强化创新药研发与商业化布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2604729910","media":"中金财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604729910?lang=zh_cn&edition=full","pubTime":"2026-01-17 09:37","pubTimestamp":1768613826,"startTime":"0","endTime":"0","summary":"中访网数据 健康元药业集团股份有限公司于2026年1月16日召开第九届董事会第十五次会议，审议并通过了关于高级管理人员聘任的议案。董事会同意任命张庆雷先生为公司副总裁，全面负责公司药政法规事务相关工作，旨在加速公司创新药研发与商业化进程，推动创新药产品管线的临床研究申请和新药上市申请。张庆雷先生的任期自董事会表决通过之日起，至公司第九届董事会任期届满之日止。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260117/31950329.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["600380","BK1574","BK0114","06978","BK0239","BK0028","159992","BK0046","BK0188","BK0077","BK1161"],"gpt_icon":0},{"id":"2601879557","title":"健康元(600380.SH)：莱康奇塔单抗注射液被纳入优先审评审批程序","url":"https://stock-news.laohu8.com/highlight/detail?id=2601879557","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601879557?lang=zh_cn&edition=full","pubTime":"2026-01-07 17:41","pubTimestamp":1767778878,"startTime":"0","endTime":"0","summary":"智通财经APP讯，健康元(600380.SH)发布公告，公司控股子公司珠海市丽珠单抗生物技术有限公司(简称：丽珠单抗)的产品莱康奇塔单抗注射液于2025年12月26日被国家药品监督管理局药品审评中心纳入拟优先审评品种公示名单;现公示期满后，根据国家药品监督管理局药品审评中心网站信息公开显示，已纳入优先审评品种名单，正式进入药品上市许可优先审评审批程序。拟定适应症(或功能主治)：本品用于适合接受系统治疗或光疗的中重度斑块状银屑病成人患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1389898.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0188","BK0046","BK0028","BK0077","BK0114","600380"],"gpt_icon":0},{"id":"2595679943","title":"丽珠医药(01513)：健康元拟将毛孩子49%股权转让给心有毛孩","url":"https://stock-news.laohu8.com/highlight/detail?id=2595679943","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595679943?lang=zh_cn&edition=full","pubTime":"2025-12-30 18:58","pubTimestamp":1767092313,"startTime":"0","endTime":"0","summary":"智通财经APP讯，丽珠医药 发布公告，于2025年12月30日，本公司与健康元、心有毛孩及毛孩子订立增资认购及股权转让协议，心有毛孩同意对毛孩子以现金方式增资认缴人民币1500万元，同时，健康元同意将所持有毛孩子49%的股权转让给心有毛孩。本次交易完成后，心有毛孩将持有毛孩子52.56%的股权，本公司持有的毛孩子股权将从51.00%摊薄至47.44%，健康元将不再持有毛孩子股权，毛孩子不再纳入本公司合并报表范围内。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1387239.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0046","BK0077","01513","BK0028","BK1191","BK0239","BK0114","BK0188","600380"],"gpt_icon":0},{"id":"2594024272","title":"每周股票复盘：健康元（600380）NS-041片获抑郁症临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2594024272","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594024272?lang=zh_cn&edition=full","pubTime":"2025-12-28 04:25","pubTimestamp":1766867111,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，健康元报收于11.7元，较上周的11.79元下跌0.76%。本周，健康元12月22日盘中最高价报12.03元。本周关注点公司公告汇总：NS-041片获准开展治疗抑郁症的临床试验公司公告汇总：莱康奇塔单抗注射液上市许可申请已获受理公司公告汇总健康元药业集团股份有限公司控股子公司丽珠集团丽珠制药厂收到国家药品监督管理局签发的《药物临床试验批准通知书》，同意NS-041片新增适应症“治疗抑郁症”开展临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800001099.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0114","600380","BK0046","BK0077","BK0188","BK0028","BK0239"],"gpt_icon":0},{"id":"2593475214","title":"健康元最新公告：莱康奇塔单抗注射液上市许可申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2593475214","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593475214?lang=zh_cn&edition=full","pubTime":"2025-12-24 17:55","pubTimestamp":1766570145,"startTime":"0","endTime":"0","summary":"健康元(600380.SH)公告称，控股子公司丽珠单抗“莱康奇塔单抗注射液”的境内生产药品注册上市许可申请获国家药监局受理。该药品用于适合接受系统治疗或光疗的中重度斑块状银屑病成人患者。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400029377.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0239","600380","BK0188","BK0028","BK0114","BK0046"],"gpt_icon":0},{"id":"2593852474","title":"健康元（600380）披露获得NS-041片抑郁症临床试验批准，12月22日股价上涨0.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593852474","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593852474?lang=zh_cn&edition=full","pubTime":"2025-12-22 17:53","pubTimestamp":1766397206,"startTime":"0","endTime":"0","summary":"截至2025年12月22日收盘，健康元报收于11.88元，较前一交易日上涨0.76%，最新总市值为217.34亿元。该股当日开盘11.87元，最高12.03元，最低11.81元，成交额达1.59亿元，换手率为0.73%。公司近日发布公告称，其控股子公司丽珠集团丽珠制药厂收到国家药品监督管理局签发的《药物临床试验批准通知书》，同意NS-041片新增适应症“治疗抑郁症”开展临床试验。NS-041片为化学药品1类，系新型高选择性KCNQ2/3激动剂，此前已获批开展癫痫适应症II期临床研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122200022693.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0114","600380","BK0046","BK0077","BK0188","BK0028","BK0239"],"gpt_icon":0},{"id":"2593260501","title":"健康元(600380.SH)下属子公司获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2593260501","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593260501?lang=zh_cn&edition=full","pubTime":"2025-12-21 15:51","pubTimestamp":1766303472,"startTime":"0","endTime":"0","summary":"智通财经APP讯，健康元 发布公告，近日，公司控股子公司丽珠医药集团股份有限公司的控股子公司丽珠集团丽珠制药厂收到国家药品监督管理局核准签发的关于NS-041片新增针对“治疗抑郁症”适应症的《药物临床试验批准通知书》，同意NS-041片新增适应症开展临床试验。2023年12月27日，NS-041片获批开展“癫痫”适应症的临床试验，目前该适应症正在进行II期临床研究。本次NS-041片新增获批的临床试验适应症为“治疗抑郁症”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384094.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0188","BK0114","BK0239","600380","BK0046","BK0077"],"gpt_icon":0},{"id":"2593126756","title":"健康元最新公告：控股子公司获得NS-041片新增抑郁症临床试验批准通知书国内尚无新一代靶向KCNQ2/3的药物上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2593126756","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593126756?lang=zh_cn&edition=full","pubTime":"2025-12-21 15:41","pubTimestamp":1766302885,"startTime":"0","endTime":"0","summary":"健康元公告称，公司控股子公司丽珠制药厂收到国家药品监督管理局核准签发的关于NS-041片新增针对“治疗抑郁症”适应症的《药物临床试验批准通知书》。NS-041片是一款新型高选择性KCNQ2/3激动剂，目标用于癫痫和抑郁症等神经精神类疾病的治疗，系目前国内唯一获批同时开展癫痫和抑郁症临床研究的KCNQ2/3 靶向药物。截至公告披露日，国内尚无新一代靶向KCNQ2/3的药物上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122100001519.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600380","BK0188","BK0114","BK0046","BK0077","BK0028","BK0239"],"gpt_icon":0},{"id":"2590595908","title":"健康元(600380.SH)：玛帕西沙韦胶囊获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2590595908","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590595908?lang=zh_cn&edition=full","pubTime":"2025-12-11 16:35","pubTimestamp":1765442147,"startTime":"0","endTime":"0","summary":"智通财经APP讯，健康元(600380.SH)公告，公司收到国家药品监督管理局核准签发的《药品注册证书》，药品名称为：玛帕西沙韦胶囊。玛帕西沙韦胶囊(壹立康®)为公司创新抗流感1类新药，适用于既往健康的12岁及以上青少年和成人单纯性甲型和乙型流感患者的治疗，不包括存在流感相关并发症高风险的患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380365.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"健康元(600380.SH)：玛帕西沙韦胶囊获药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0114","BK0239","BK0028","BK0188","BK0077","BK0046","600380"],"gpt_icon":0},{"id":"2590936783","title":"健康元药业集团多款核心产品纳入新版国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2590936783","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590936783?lang=zh_cn&edition=full","pubTime":"2025-12-09 10:04","pubTimestamp":1765245892,"startTime":"0","endTime":"0","summary":"中访网数据 2025年12月7日，国家医疗保障局正式发布《国家基本医疗保险、生育保险和工伤保险药品目录》。健康元药业集团股份有限公司及其下属子公司共有218个产品被纳入新版目录，其中甲类94个，乙类124个。本次调整中，公司多款核心及创新产品取得积极进展。新版国家医保目录将于2026年1月1日起正式执行。此次公司主力及创新产品纳入或续约医保，预计将有利于提升相关药品的可及性和市场渗透率，对公司未来的经营业绩产生积极影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251209/31852478.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0077","600380","BK0114","BK0239","BK0188","BK0046","BK0028"],"gpt_icon":0},{"id":"2589433879","title":"健康元(600380.SH)及下属子公司共有218个产品纳入医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589433879","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589433879?lang=zh_cn&edition=full","pubTime":"2025-12-08 16:21","pubTimestamp":1765182077,"startTime":"0","endTime":"0","summary":"智通财经APP讯，健康元(600380.SH)发布公告，本次公司及下属子公司共有218个产品纳入《医保目录》，其中甲类94个，乙类124个。其中：注射用阿立哌唑微球通过谈判纳入医保目录，注射用醋酸曲普瑞林微球新增适应症，妥布霉素吸入溶液、注射用艾普拉唑钠续约成功。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378761.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"健康元(600380.SH)及下属子公司共有218个产品纳入医保目录","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0114","BK0077","BK0239","BK0188","600380","BK0046","BK0028"],"gpt_icon":0},{"id":"2589813866","title":"健康元（600380）披露第二期中长期事业合伙人持股计划存续期六个月后届满提示，12月5日股价下跌0.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589813866","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589813866?lang=zh_cn&edition=full","pubTime":"2025-12-05 22:23","pubTimestamp":1764944606,"startTime":"0","endTime":"0","summary":"截至2025年12月5日收盘，健康元报收于12.64元，较前一交易日下跌0.24%，最新总市值为231.24亿元。公司近日发布公告称，健康元药业集团第二期中长期事业合伙人持股计划存续期将于2026年6月7日届满。该持股计划已于2022年6月7日前完成股票购买，累计购入公司股票6,275,372股，占公司当前总股本的0.34%。存续期届满前，管理委员会将根据规定及市场情况决定股份处置、是否延期或进行清算分配。公司将在后续严格遵守信息披露要求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120500040465.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0114","BK0077","BK0239","BK0188","600380","BK0046","BK0028"],"gpt_icon":0},{"id":"2586925400","title":"健康元药业集团召开2025年第三季度业绩说明会，披露创新药进展与海外布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2586925400","media":"中金财经","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586925400?lang=zh_cn&edition=full","pubTime":"2025-11-26 08:04","pubTimestamp":1764115454,"startTime":"0","endTime":"0","summary":"中访网数据 健康元药业集团股份有限公司于2025年11月25日通过网络方式召开了2025年第三季度业绩说明会。此外，多款呼吸领域1类创新药处于II期及以上临床阶段。在海外市场方面，公司已在菲律宾、荷兰设立子公司以拓展东南亚及欧盟市场，多款吸入制剂正推进多区域注册，控股子公司丽珠集团的多款产品也已在巴基斯坦等国获批或申报。丽珠集团引进的新型佐剂四价重组蛋白流感疫苗已进入I期临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251126/31823553.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["600380","BK1161","BK0239","BK0028","BK0114","BK1574","BK0046","BK0188","BK0077","159992","06978"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1773959869940,"stockEarnings":[{"period":"1week","weight":-0.0151},{"period":"1month","weight":-0.0298},{"period":"3month","weight":-0.0611},{"period":"6month","weight":-0.127},{"period":"1year","weight":-0.0181},{"period":"ytd","weight":-0.0416}],"compareEarnings":[{"period":"1week","weight":-0.0297},{"period":"1month","weight":-0.0185},{"period":"3month","weight":0.0298},{"period":"6month","weight":0.0488},{"period":"1year","weight":0.1693},{"period":"ytd","weight":0.0095}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"健康元药业集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"81433人(较上一季度增加6.79%)","perCapita":"22465股","listingDate":"2001-06-08","address":"广东省深圳市南山区高新区北区朗山路17号健康元药业集团大厦","registeredCapital":"182945万元","survey":" 健康元药业集团股份有限公司的主营业务是医药产品及保健品研发、生产及销售。公司的主要产品是化学制剂、生物制品、化学原料药及中间体、中药制剂、诊断试剂及设备、保健食品。公司凭借扎实的研发生产实力成功入选2025中国药品研发综合实力50强。","listedPrice":24.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"健康元(600380)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供健康元(600380)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"健康元,600380,健康元股票,健康元股票老虎,健康元股票老虎国际,健康元行情,健康元股票行情,健康元股价,健康元股市,健康元股票价格,健康元股票交易,健康元股票购买,健康元股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"健康元(600380)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供健康元(600380)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}